Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.

Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity

Open access
Ortmann, Brian M · 2024 · BMJ Oncology

Abstract

Cancer remains one of the most formidable challenges in modern medicine, due to its complex and dynamic nature, which demands innovative therapeutic approaches. One major challenge to cancer treatment is the tumour microenvironment and in particular tumour hypoxia (low oxygen levels), which contributes to tumour progression and immune evasion. At the cellular level, this is primarily governed by hypoxia-inducible factor (HIF). HIF is a transcription factor that orchestrates cellular responses to low oxygen levels, driving angiogenesis, metabolic adaptation and immune regulation. HIF’s dysregulation is frequently observed in various cancer types and correlates with increased aggressiveness, metastasis, resistance to therapy and poor patient prognosis. Consequently, understanding the cellular mechanisms underlying HIF activation and its downstream effects has become crucial to developing targeted cancer therapies for improving cancer patient outcomes and represents a key step towards precision medicine. Recent advancements in drug development have led to the emergence of HIF inhibitors, which aim to disrupt HIF-driven processes in cancer providing therapeutic benefit. Here, we provide a review of the molecular mechanisms through which HIF promotes tumour growth and resistance, emphasising the potential clinical benefits of HIF-targeted therapies. This review will discuss the challenges and opportunities associated with translating HIF inhibition into clinical practice, including ongoing clinical trials and future directions in the development of HIF-based cancer treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjonc-2023-000154

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HIF subunit composition. The domain structure of different HIF isoforms is depicted as follows. The basic Helix-Loop-Helix (bHLH) and Per-ARNT-Sim (PAS) domains are essential for DNA binding and dimerisation. Within HIF-α subunits, the oxygen-dependent degradation domain (ODD) imparts sensitivity to oxygen levels. Notably, the ODD region contains conserved proline residues, subject to hydroxylation in an oxygen-dependent manner by prolyl hydroxylase (PHD) enzymes. Additionally, the transactivation domain (TAD) is crucial for achieving full transcriptional activity. HIF-3α presents a greater complexity, featuring multiple splice variants that exert diverse biological effects. Of particular significance, HIF-3 is unique among the subunits in possessing an LZIP motif, which also confers DNA binding capabilities.
Figure 1 HIF subunit composition. The domain structure of different HIF isoforms is depicted as follows. The basic Helix-Loop-Helix (bHLH) and Per-ARNT-Sim (PAS) domains are essential for DNA binding and dimerisation. Within HIF-α subunits, the oxygen-dependent degradation domain (ODD) imparts sensitivity to oxygen levels. Notably, the ODD region contains conserved proline residues, subject to hydroxylation in an oxygen-dependent manner by prolyl hydroxylase (PHD) enzymes. Additionally, the transactivation domain (TAD) is crucial for achieving full transcriptional activity. HIF-3α presents a greater complexity, featuring multiple splice variants that exert diverse biological effects. Of particular significance, HIF-3 is unique among the subunits in possessing an LZIP motif, which also confers DNA binding capabilities.CC BY-NC · PubMed Central
Figure 2 Regulation of HIF by oxygen. Under normal oxygen conditions, HIF-α subunits are hydroxylated by prolyl hydroxylase (PHD) enzymes in an oxygen-dependent manner. This hydroxylation marks them for proteasomal degradation by creating a binding affinity for the E3 Ligase VHL. In contrast, under hypoxic conditions, PHD activity is inhibited, leading to the stabilisation and translocation of HIF-α subunits to the nucleus. There, they heterodimerise with HIF-1β, and activate the transcription of target genes involved in adaptation to low oxygen environments. HIF, hypoxia-inducible factor; VHL, von Hippel-Lindau.
Figure 2 Regulation of HIF by oxygen. Under normal oxygen conditions, HIF-α subunits are hydroxylated by prolyl hydroxylase (PHD) enzymes in an oxygen-dependent manner. This hydroxylation marks them for proteasomal degradation by creating a binding affinity for the E3 Ligase VHL. In contrast, under hypoxic conditions, PHD activity is inhibited, leading to the stabilisation and translocation of HIF-α subunits to the nucleus. There, they heterodimerise with HIF-1β, and activate the transcription of target genes involved in adaptation to low oxygen environments. HIF, hypoxia-inducible factor; VHL, von Hippel-Lindau.CC BY-NC · PubMed Central
Figure 3 HIF regulates multiple processes involved in tumour progression. In the tumour microenvironment, hypoxia or low oxygen levels, leads to the stabilisation of HIF-1α and HIF-2α subunits. HIF-α subunits translocate to the nucleus, where they heterodimerise with HIF-β and bind to hypoxia response elements (HREs) in the promoter regions of target genes. HIF activation results in the transcription of genes that promote various aspects of cancer progression, including angiogenesis, metastasis, metabolic reprogramming and resistance to therapy. These HIF-driven processes collectively contribute to the aggressiveness and therapeutic challenges associated with cancer. Figure highlights some key gene targets that can influence cancer progression. HIF, hypoxia-inducible factor.
Figure 3 HIF regulates multiple processes involved in tumour progression. In the tumour microenvironment, hypoxia or low oxygen levels, leads to the stabilisation of HIF-1α and HIF-2α subunits. HIF-α subunits translocate to the nucleus, where they heterodimerise with HIF-β and bind to hypoxia response elements (HREs) in the promoter regions of target genes. HIF activation results in the transcription of genes that promote various aspects of cancer progression, including angiogenesis, metastasis, metabolic reprogramming and resistance to therapy. These HIF-driven processes collectively contribute to the aggressiveness and therapeutic challenges associated with cancer. Figure highlights some key gene targets that can influence cancer progression. HIF, hypoxia-inducible factor.CC BY-NC · PubMed Central
Figure 4 Regulators of HIF transcriptional activity. Diagram illustrating the categorised regulators of HIF transcriptional activity during hypoxia, segmented based on their functional roles. Proteins highlighted in green serve as positive regulators, enhancing HIF activity, while those in red function as negative regulators, suppressing HIF activity. HIF, hypoxia-inducible factor.
Figure 4 Regulators of HIF transcriptional activity. Diagram illustrating the categorised regulators of HIF transcriptional activity during hypoxia, segmented based on their functional roles. Proteins highlighted in green serve as positive regulators, enhancing HIF activity, while those in red function as negative regulators, suppressing HIF activity. HIF, hypoxia-inducible factor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

4 retracted

Show all 227 references

Research works printed but not linked: 1

  1. 10.1038/s41577-020-0306 · doi:10.1038/s41577-020-0306

Cited by

See all 68

Metadata

Authors
Ortmann, B. M.
Affiliations
Newcastle University (GB)
Corresponding author
Ortmann, Brian M
Venue
BMJ Oncology
Publisher
BMJ
Published
2024-02
Volume
3
Issue
1
Pages
e000154
ISSN
2752-7948 (ISSN-L)
OpenAlex
W4391451249
Cited by
67
References
227
Citations by year
2026: 17 · 2025: 38 · 2024: 12
FWCI
3.27
Type
journal article
Language
en
Open access
Locations
  • BMJ Oncology (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc)
Funders
Faculty of Medical Sciences, Newcastle University (NUAcT Fellowship STR/0260/NACT/BO 02)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
hypoxia-inducible factor, tumor hypoxia, tumor microenvironment, HIF inhibitors, angiogenesis, cancer metabolism, immune evasion, treatment resistance, metastasis, HIF-targeted therapy, clinical translation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. https://app.cochat.ai/papers/10.1136/bmjonc-2023-000154
The paper
Ortmann, B. M. (2024). Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncology. https://doi.org/10.1136/bmjonc-2023-000154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.